Will the FDA approve any psychedelic substance for medical use this year?
2.0 pts (24h)Health & MedicineOne-Off3m
KalshiComprobar disponibilidadKYC requerido2% de comisiónDatos de resolución verificadosCalibración aceptableProbabilidad implícita actual
No 74%
Calidad del mercado
65 / 100
Calidad mediaVolumen 24h
251,5 €
Liquidez
77 mil €
Alta liquidezCompra / Venta
26.0% / 31.0%
Spread
5.0 pt
Spread moderadoDatos de mercado
Actualizado hace 3 minutos
17 jul 25, 14:00 UTC1 ene 27, 4:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
Will the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsWill the FDA approve MDMA for PTSD?
KalshiWill the FDA approve a psilocybin treatment during 2026?
FutuurWill a psychedelic substance get de-scheduled by the US by 2030?
Manifold MarketsReglas
If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.
- Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.
- Important information: For purposes of this Contract:
- The listed substances are illustrative, not exhaustive.
- Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion.
- "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product.
Mercados abiertos
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No-0.2pt97%
- Yes+0.2pt3%
- Volumen total
- 15,6 M €
- Volumen 24h
- 30,4 mil €
POLYMARKETEbola pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volumen total
- 652,8 mil €
- Volumen 24h
- 3,5 mil €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No97%
- Yes-0.7pt3%
- Volumen total
- 1,6 M €
- Volumen 24h
- 2,9 mil €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000+1.0pt97%
- Above 600059%
+2 resultados más
- Volumen total
- 865,3 mil €
- Volumen 24h
- 2,7 mil €
POLYMARKETNew pandemic in 2026?
- No+1.0pt94.1%
- Yes-1.0pt5.9%
- Volumen total
- 915,3 mil €
- Volumen 24h
- 1,4 mil €
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+1.0pt65%
- September41%
- June28%
- Volumen total
- 84 mil €
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will 3 mg THC beverages be federally legal to sell?
- Cyclosporiasis cases reported in the US in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Measles cases in U.S. in 2026?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
Preguntas frecuentes
- ¿Cuáles son las probabilidades actuales de Will the FDA approve any psychedelic substance for medical use this year??
- Kalshi cotiza No al 74% a fecha de 9 de septiembre de 2026.
- ¿Cuándo se resuelve Will the FDA approve any psychedelic substance for medical use this year??
- Está previsto que Will the FDA approve any psychedelic substance for medical use this year? se resuelva el 1 de enero de 2027.
- ¿Cómo se liquida Will the FDA approve any psychedelic substance for medical use this year??
- Kalshi liquida este mercado del siguiente modo: If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.